Abstract
Although there were a lot of weakly active animal toxins in the venoms, their values and applications are still mysterious, such as BF9, which is a Kunitz-type toxin isolated from the venom of the elapid snake Bungarus fasciatus. Here, we used BF9 to be a molecular scaffold, and engineered eight BF9-derived peptides by changing P1 site Asn17 of BF9, such as BF9-N17Y and BF9-N17T designed from the polar subfamily, BF9-N17L and BF9-N17G designed from the Non-polar subfamily, BF9-N17D designed from acidic subfamily, and BF9-N17H, BF9-N17K and BF9-N17R designed from basic subfamily. Through enzyme inhibitor experiment assays, we found a potent and selective chymotrypsin inhibitor BF9-N17Y, a potent and selective coagulation factor XIa inhibitor BF9-N17H, and two highly potent coagulation factor XIa inhibitors BF9-N17K and BF9-N17. APTT and PT assays further showed that BF9-N17H, BF9-N17K and BF9-N17R were three novel anticoagulants with selectively intrinsic coagulation pathway inhibitory activity. Considering that natural weakly active animal toxins are also a huge peptide resource, our present work might open a new window about pharmacological applications of weakly active animal toxins, which might be good templates for potent a...Continue Reading
References
Aug 16, 2000·Thrombosis Research·A V Pokhilko
Sep 20, 2001·The Journal of Biological Chemistry·C ChenS H Wu
Dec 17, 2003·The Biochemical Journal·Stéphanie MouhatJean-Marc Sabatier
Jun 1, 2005·Toxicon : Official Journal of the International Society on Toxinology·E V KryukovaV I Tsetlin
Aug 1, 2006·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Lior CohenDalia Gordon
Mar 29, 2007·Journal of Thrombosis and Haemostasis : JTH·D Gailani, T Renné
Oct 6, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·David Gailani, Thomas Renné
Dec 25, 2007·The Journal of Pharmacology and Experimental Therapeutics·Michel DemeuleRichard Béliveau
Oct 17, 2008·PloS One·Chun-Hua YuanSong-Ping Liang
Nov 4, 2008·Cellular and Molecular Life Sciences : CMLS·L St PierreM F Lavin
Jul 31, 2009·Annual Review of Genomics and Human Genetics·Bryan G FryRicardo C Rodríguez de la Vega
May 14, 2010·PloS One·Marcel Schmidt Am BuschThomas Simonson
Dec 1, 2010·The Journal of Biological Chemistry·Madhu S BajajS Paul Bajaj
Feb 23, 2012·The Journal of Biological Chemistry·Zong-Yun ChenYing-Liang Wu
May 25, 2012·Molecular Pharmacology·Zoltan VargaGyorgy Panyi
Sep 20, 2012·Nature Communications·Nicholas R CasewellWolfgang Wüster
Jun 5, 2013·Proceedings of the National Academy of Sciences of the United States of America·Sanjeev Kumar UpadhyayK George Chandy
Jun 19, 2013·Marine Drugs·Caroline B F Mourão, Elisabeth F Schwartz
Nov 19, 2013·Journal of Biochemical and Molecular Toxicology·Weishan YangZongyun Chen
Dec 20, 2013·Toxins·Timothy N W JacksonBryan G Fry
Aug 5, 2014·Journal of Molecular Biology·Jeet KaliaFrank Bosmans
Nov 25, 2014·Journal of Thrombosis and Haemostasis : JTH·W ChenT S Kang
Dec 17, 2015·Pharmacological Reviews·Barbara MulloyClive P Page
Jun 10, 2016·PLoS Neglected Tropical Diseases·Cassandra M Modahl, Stephen P Mackessy
Jul 5, 2016·Thrombosis Research·Brian C Cooley
Sep 18, 2016·Hematology/oncology Clinics of North America·Allison P Wheeler, David Gailani
Jan 18, 2017·Microbial Cell Factories·Jeremy TurchettoRenaud Vincentelli
Oct 17, 2017·Toxins·Matan GeronAvi Priel
Nov 22, 2017·ACS Chemical Neuroscience·Ying WuZhengyu Cao
Feb 11, 2018·Cellular and Molecular Life Sciences : CMLS·Andrew A WalkerGlenn F King
Citations
Dec 12, 2018·Journal of Biochemical and Molecular Toxicology·Simran KaurRobin Doley
Jul 23, 2020·Journal of Molecular Evolution·Manasi Mishra
Jan 20, 2021·PLoS Neglected Tropical Diseases·Fábio MambelliSergio C Oliveira
Dec 31, 2020·Pharmaceuticals·Manasi MishraShailja Singh
Apr 4, 2021·International Journal of Molecular Sciences·Vincent MariauleMoez Rhimi